CanaQuest Achieves Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD

Drug Candidate, CQ-001 (cannabidiol "CBD" + IP formula), also demonstrated substantially reduced seizures at higher doses, with less CBD, compared to standard CBD.

TORONTO, ON / ACCESSWIRE / December 8, 2022 / CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced Statistically Significant efficacy results from the Clinical Dose & Efficacy Study ("Study") conducted by Dr. W McIntyre Burnham, emeritus professor of the University of Toronto's Temerty Faculty of Medicine. In comparison to standard CBD, CQ-001 (cannabidiol "CBD" + IP formula - essential fatty acids) demonstrated 40% more seizure reduction at a medium dose in the maximal electroshock seizure (MES) model. This result indicates that CQ-001 is stronger than standard CBD, and could be used a lower dose to achieve seizure control.

Highlights derived from the Study are as follows:

• The enhanced efficacy from these clinical studies further validates the pre-clinical trial results obtained by Dr. Steven Laviolette, a professor and neuroscientist, at Western University.
• These results set the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects and will define a dosage of CQ-001 for a clinical trial (Phase II/III, double-blind trial, 60 patients).
• CanaQuest has identified the regulatory pathways to obtain Rx Drug Identification Numbers (DINs) in Canada and the USA for Epilepsy rare neurological conditions. CQ-001, in combination with its proprietary processing and delivery method, is estimated to be approved in about 3 years.

"Further testing will be necessary, however preliminary tests suggest that CQ-001 is stronger than regular CBD," said Burnham, pharmacologist and co-director of EpLink.

Paul Ramsay, President, stated, "The Clinical Study results reconfirm the pre-clinical trial results conducted at Western University, and further substantiate the magnitude of this life-changing discovery."

Physicians, psychiatrists, pharmacists, and healthcare practitioners interested in joining our growing network can contact [e-mail].

About: The Ontario Brain Institute - EpLink

The Ontario Brain Institute is a provincially funded, not-for-profit organization that accelerates discovery and innovation, benefiting both patients and the economy. https://braininstitute.ca/about-obi